Evidence map›Paper›PMID 34755036›Full record

ArticleJournal of the Canadian Association of Gastroenterology2021

Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Children and Expectant Mothers With Inflammatory Bowel Disease.

Eric I Benchimol, Matthew W Carroll, Rose Geist, Anne M Griffiths, James Guoxian Huang, David R Mack, Charles N Bernstein, Alain Bitton, Jennifer L Jones, Gilaad G Kaplan and 8 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the Canadian Association of Gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. The 2023 Impact of Inflammatory Bowel Disease in Canada: COVID-19 and IBD.Journal of the Canadian Association of Gastroenterology · 2023
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 2 countries.

Eric I BenchimolSickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
Matthew W CarrollDepartment of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
Rose GeistDepartment of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Anne M GriffithsSickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
James Guoxian HuangSickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
David R MackCHEO Inflammatory Bowel Disease Centre and Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada.
Charles N BernsteinDepartment of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Alain BittonDepartment of Medicine, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
Jennifer L JonesDepartment of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Gilaad G KaplanDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.
M Ellen KuenzigSickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
Kate LeeCrohn's and Colitis Canada, Toronto, Ontario, Canada.
Mariam S MukhtarDepartment of Internal Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Sanjay K MurthyThe Ottawa Hospital IBD Centre, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Parul TandonDivision of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-0021-2161
Laura E TargownikDivision of Gastroenterology and Hepatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Joseph W WindsorDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.
Cynthia H SeowDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID https://orcid.org/0000-0002-1551-9054
University of Calgary · CAUniversity of Toronto · CAMount Sinai Hospital · CASickKids Foundation · CAUniversity of Ottawa · CACrohn's and Colitis Canada · CADalhousie University · CAKing Abdulaziz University · SAMcGill University Health Centre · CAUniversity of Alberta · CAUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) in children with inflammatory bowel disease (IBD) typically results in a mild infection, similar to those without IBD. Children and adolescents have less severe manifestations of COVID-19 compared to older people, whether or not they have IBD. However, some IBD medications (in particular, corticosteroids) are associated with more severe COVID-19. During the first year of the global pandemic, more IBD care was provided with online technology, necessitated by efforts to reduce hospital and clinic visits. Additionally, non-endoscopic monitoring of inflammation has been required due to the cancellation of non-urgent procedures, resulting in longer endoscopy wait-times. In contrast, pregnant people (with and without IBD) who contract COVID-19 are at increased risk of severe manifestations, death and preterm delivery, making them a priority for severe acute respiratory syndrome coronavirus 2 protective measures and vaccination. Few studies have examined effect of COVID-19 on IBD-related disease activity in pregnant people with IBD. The pandemic has significantly affected the mental health and sense of well-being of children and their families, as well as pregnant people with IBD. These groups were much more likely to experience anxiety and depression compared with prior to the pandemic, even while concern has mostly abated regarding the effect of IBD medications and COVID-19 severity. Unfortunately, the availability of mental health care providers who specialize in people with IBD has not kept pace with the increasing demand.

Indexed as

Coronavirus disease 2019 (COVID-19)Crohn’s diseaseEpidemiologyInflammatory bowel diseaseMental healthPediatricsPregnancySARS-CoV-2ulcerative colitis

Identifiers

PMID34755036
PMCPMC8570420
OpenAlexW3212152323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.